Fluorine-18-THK 5351

Drug Profile

Fluorine-18-THK 5351

Alternative Names: [18F]THK-5351; F-18 THK-5351; FluoroTau; GE-216

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tohoku University
  • Developer Fundacio Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau; GE Healthcare; Tohoku University
  • Class Antidementias; Imaging agents; Pyridines; Quinolines; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Neurodegenerative disorders
  • Clinical Phase Unknown Aphasia; Lewy body disease; Mild cognitive impairment; Progressive supranuclear palsy

Most Recent Events

  • 10 Oct 2017 Phase-II clinical trials in Neurodegenerative disorders (Diagnosis) in Spain (IV) (EudraCT2015-004656-22)
  • 24 Aug 2017 Chemical structure information added
  • 18 Jul 2017 Pharmacodynamics data froma clinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top